Published in Antiviral Res on April 24, 2012
The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am J Trop Med Hyg (2010) 4.09
Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis (2009) 2.26
Diagnosis of dengue virus infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum and saliva. Clin Diagn Lab Immunol (2003) 2.22
IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol (2004) 1.50
Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis (2007) 1.33
HLA-A, -B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: advantages of the Cuban population for HLA studies of dengue virus infection. Hum Immunol (2007) 1.29
A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine (2006) 1.24
Apoptosis in tissues from fatal dengue shock syndrome. J Clin Virol (2007) 1.23
PCR detection of dengue virus using dried whole blood spotted on filter paper. J Virol Methods (2005) 1.14
Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines (2010) 1.10
Dengue 3 epidemic, Havana, 2001. Emerg Infect Dis (2004) 1.10
Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. Am J Trop Med Hyg (2010) 1.02
Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res (2008) 1.00
[Economic impact of dengue 2 epidemic in Santiago de Cuba, 1997]. Rev Cubana Med Trop (2005) 0.98
Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol (2007) 0.97
Diagnosis of dengue virus infection by the visual and simple AuBioDOT immunoglobulin M capture system. Clin Diagn Lab Immunol (2003) 0.97
Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals. Viral Immunol (2006) 0.95
[Dengue and hemorrhagic dengue in the Americas]. Rev Panam Salud Publica (2007) 0.95
Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res (2006) 0.94
Fatal severe dengue and cell death in sickle cell disease during the 2001-2002 Havana dengue epidemic. Int J Infect Dis (2008) 0.93
A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology (2009) 0.93
Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol (2008) 0.93
Dengue virus type 3, Cuba, 2000-2002. Emerg Infect Dis (2005) 0.92
[Society, economy, inequities and dengue]. Rev Cubana Med Trop (2013) 0.92
Long-term memory cellular immune response to dengue virus after a natural primary infection. Int J Infect Dis (2002) 0.91
The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol (2009) 0.88
Association of MICA and MICB alleles with symptomatic dengue infection. Hum Immunol (2011) 0.88
Antibody responses to Asian and American genotypes of dengue 2 virus in immunized mice. Clin Diagn Lab Immunol (2005) 0.87
Oxidative stress in adult dengue patients. Am J Trop Med Hyg (2004) 0.87
Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg (2003) 0.87
A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods (2004) 0.87
A myocarditis outbreak with fatal cases associated with adenovirus subgenera C among children from Havana City in 2005. J Clin Virol (2008) 0.86
Viremia and the magnitude of the immune response upon infection of green monkeys with dengue virus type 2 are strain-dependent. Curr Microbiol (2009) 0.86
Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: a potential model for vaccine testing. Microbiol Immunol (2009) 0.85
Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine (2008) 0.85
Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J (2006) 0.85
Apoptosis, vascular leakage and increased risk of severe dengue in a type 2 diabetes mellitus patient. Diab Vasc Dis Res (2008) 0.83
The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. Clin Vaccine Immunol (2011) 0.83
A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem (2004) 0.83
Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes. Clin Vaccine Immunol (2009) 0.82
Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis (2009) 0.82
Ubiquitous expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice. Neurosci Lett (2005) 0.82
Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction. Clin Sci (Lond) (2007) 0.82
Dual infection with hepatitis A and E viruses in outbreaks and in sporadic clinical cases: Cuba 1998-2003. J Med Virol (2008) 0.82
Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res (2008) 0.81
A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine (2006) 0.81
Enzyme-linked immunosorbent assay for quantitative determination of capsular polysaccharide production in Streptococcus pneumoniae clinical isolates. Biotechnol Appl Biochem (2006) 0.80
In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. Arch Virol (2009) 0.80
Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol (2009) 0.80
Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine (2005) 0.80
The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine (2011) 0.80